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Primary adrenal insufficiency is characterized by low 
or subnormal serum cortisol and elevated levels of 
adrenocorticotropic hormone (ACTH). Patients also have 
low aldosterone and elevated plasma renin. Elevated 
ACTH and low aldosterone distinguish primary adrenal 
insufficiency from secondary adrenal insufficiency, where 
cortisol is low with low ACTH and normal aldosterone. 
Other biochemical disturbances in primary adrenal 
insufficiency are hyponatremia (84–88%), hyperkalemia 
(36–64%) and elevated TSH (50%) (1). Clinically, fatigue 
and weight loss is reported in 100%, anorexia and nausea/
vomiting in 80–90%, hyperpigmentation in >90% and 
low blood pressure in 90% (2). ACTH stimulation test 
confirms the diagnosis. The condition may progress to 
adrenal crisis and death. Causes of adrenal insufficiency 
include autoimmune adrenalitis, infections, infiltrative 
disorders and malignancy. We hereby report two patients 
presenting with adrenal insufficiency with negative 
21-hydroxylase antibodies and bilateral adrenal lesions.
Case presentations
Case report 1
A 70-year-old man with former mechanical ileus and 
gout experienced 12 kg weight loss, nausea, anorexia, 
orthostatic dizziness and joint pain. Because of an elevated 
creatinine at 250 µmol/L, he was admitted for evaluation 
of kidney failure.
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Investigations
Blood pressure was 96/70 mmHg, serum sodium: 133 
mmol/L (137–145 mmol/L) and serum potassium: 6.2 
mmol/L (3.5–5.0 mmol/L). On clinical suspicion, a 
paired morning cortisol and ACTH was taken, revealing 
cortisol at 98 nmol/L (112–502 nmol/L) and ACTH at 164 
pmol/L (1.4–14 pmol/L). A synacthen test (250 µg i.v.) 
showed no increase in cortisol. Replacement treatment 
was commenced with excellent effect. 21-hydroxylase 
autoantibodies were negative, and contrast-enhanced CT 
revealed bilateral adrenal masses, a 4.3 x 2.5 cm lesion on 
the right side and a 2.1 x 1.8 cm lesion on the left side. A 
subsequent biopsy showed diffuse large B-cell lymphoma.
Treatment and follow-up
He received six treatments with cyclophosphamide, 
vincristine, doxorubicine and prednisolone (CHOP) 
followed by radiation therapy. Replacement therapy with 
cortisone acetate 25 mg twice daily and fludrocortisone 
0.15 mg was started. Nine years after treatment, he was 
diagnosed with CNS lymphoma and died about 5 months 
later.
Case report 2
A 79-year-old man with prior testicular and bladder 
cancer, deep venous thrombosis and mild hypothyroidism 
presented with acute kidney failure. Prior to admission, 
he had 1 month history of weight loss, fatigue and 
nausea/vomiting. At presentation, his regular medication 
consisted of thyroxine replacement therapy, tamsulosin 
and low-molecular weight heparin (the latter instead of 
oral anticoagulation due to bleeding tendency).
Investigations
Biochemistry showed acute kidney failure (creatinine 
265 µmol/L) and hyponatremia (131 mmol/L). During 
the next 3 days, plasma sodium decreased to 120 mmol/L 
despite treatment with i.v. isotonic sodium chloride. 
Urinary sodium was 26 at presentation, increasing to 
68 during treatment. Urine osmolality was 392 mosm/
kg measured at the same time as the second urinary 
sodium. The first urine sodium could be explained 
by hypovolemia. Increasing urinary sodium content 
with falling plasma sodium raised suspicion of SIADH. 
Further assessment revealed low serum cortisol at 37 
nmol/L (112–502 nmol/L) and grossly elevated ACTH at 
87.7 pmol/L (1.4–14 pmol/L). Synacthen test (250 µg 
i.v.) confirmed primary adrenal insufficiency (Table 1). 
On reconsideration, this explained hyponatremia with 
high urinary sodium. Because of negative 21-hydroxylase 
antibodies, a CT scan was undertaken, revealing bilateral 
adrenal masses (Fig. 1A). The right lesion consisted of 
two parts: a ventral lesion with diameter 1.8 cm and 
precontrast density 25 Hounsfield Units (HU) and a 
dorsal part measuring 1.6 cm with precontrast density 
30 HU. Washout was 74% for the ventral lesion and 55% 
for the dorsal lesion. On the left side, the mass measured 
4.2 x 2.1 cm with precontrast density 32 HU and washout 
32% (Fig. 1B). High precontrast density and modest 
washout of the right dorsal lesion and the left mass was 
suggestive of metastases. There were no other signs of 
malignancy. Normal plasma metanephrines excluded 
pheochromocytoma.
Treatment and follow-up
Recovery was rapid after stabilization with i.v. 
hydrocortisone 100 mg intravenously three times during 
the first 24 h followed by oral replacement therapy 
with cortisone acetate 25 mg x 3 with gradual reduction 
to 25 + 12.5 mg and fludrocortisone 0.1 mg daily. MRI 
after 4 weeks confirmed bilateral adrenal lesions with 
characteristics pointing toward malignancy. He was 
planned for a CT-guided biopsy. Due to the Easter 
vacation and a mistake concerning the appointment, it 
took almost 1.5 months from the MRI (2.5 months from 
first presentation) until biopsy was scheduled. By then, 
the malignant-looking masses had almost disappeared. 
The right ventral lesion was unchanged, whereas the right 
dorsal lesion was undetectable and the left measured 8 mm 
Table 1 Baseline laboratory values and synacthen test.
Patient 1 Patient 2 Reference
S-cortisol, nmol/L
 0 193 37 112–502
 30min 175 46









Aldosterone, pmol/L <69 97 <653*
Renin, mIU/L 4.8 27.8 2.8–39.9*
*Laying down.
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(Fig. 2). Biopsy was not performed. On reconsideration, 
the lesions were thought to represent hemorrhage or 
infection with spontaneous recovery. The patient was 
in good condition on replacement therapy with regular 
follow-up at the endocrinology outpatient clinic.
Six months later he presented acutely with fever, 
tachycardia and hypotension without focal infection 
signs. Prior to admission, he had a 3 months history 
of abdominal discomfort, nausea and 10 kg weight 
reduction with a positive test for occult fecal bleeding. 
Gastrointestinal pathology had been excluded by 
endoscopic examinations. Subsequent abdominal CT 
had revealed a large mass in relation to the right adrenal. 
This finding was not yet evaluated. On acute admission, 
he had progressive systemic inflammatory response 
syndrome despite therapy with i.v. fluids, hydrocortisone 
and broad spectrum antibiotics. No infection was 
identified on urinary analyses and pulmonary X-ray. 
Abdominal CT confirmed a heterogenous tumor of the 
right adrenal measuring 6.0 x 7.0 x 12.0 cm (Fig. 3A), 
growing into liver parenchyma and infiltering adjacent 
lymph nodes. The left adrenal was atropic (Fig. 3B). A 
biopsy was performed, showing aggressive diffuse large 
B-cell lymphoma with high proliferation index (Ki67 of 
100%). Standard treatment with six courses of rituximab, 
cyclophosphamide, vincristine, doxorubicine and 
prednisolone (R-CHOP) followed by radiation therapy 
was initiated. Therapy was successful without signs of 
tumor recurrence at last follow-up, 2 years after treatment. 
The patient still takes replacement therapy for adrenal 
insufficiency and is seen by endocrinologist regularly.
Discussion
Primary adrenal lymphoma (PAL) is uncommon. In a 
systematic review by Rashidi & Fisher (3), it is defined 
Figure 1
Contrast-enhanced computed tomography (CT) of the adrenals in patient 
2 showing bilateral masses (arrows). Right-sided lesion consisting of two 
parts with ventral diameter measuring 1.8 cm and dorsal diameter 
measuring1.6cm.Theleftlesionmeasures4.2 × 2.1cm.
Figure 2
Adrenal CT 2 months later. Almost total regress of the right dorsal lesion 
and the left lesion. The right ventral lesion is still present (adenoma 
according to wash-out analyses).
Figure 3
Adrenal CT 7 months after spontaneous regress. Heterogenous tumor of 
therightadrenalmeasuring6 × 7 × 12cm(A).Atropicleftadrenalwithout
mass (B).
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as histologically proven lymphoma involving one or 
both adrenal glands, with no prior history of lymphoma 
elsewhere and adrenal lesions dominating over lymph 
nodes or other organs involved. PAL is bilateral in about 
70% of cases. Radiologically, the lesions tend to show low 
density and slight to moderate contrast enhancement 
on CT. On MRI, the tumors tend to be iso-/hypo-intense 
in T1 and hyperintense in T2 (3). In Rashidi & Fisher’s 
material, all masses studied with PET and Gallium scans 
showed increased uptake demonstrating high metabolic 
activity. Angiographic studies showed low vascularity. A 
definitive diagnosis is made histologically and requires 
biopsy. The most common subtypes are diffuse large 
B-cell lymphoma (DLBCL) accounting for 78% and 
peripheral T-cell lymphoma (PTCL) – 7%. Tumor behavior 
is aggressive with B-symptoms in 68% and adrenal 
insufficiency in 61%. Other manifestations include pain 
(42%) and fatigue (36%). Only 1% are found incidentally. 
Demographic studies show male predominance (1,8:1) 
with mean age 62 ± 14 years. Causes of bilaterality is not 
fully understood. According to Rashidi & Fisher, ‘field 
effect’ with simultaneous cancers of an anatomic ‘field’ 
(like an organ or gland) with genetically altered cells 
is one possible mechanism. Organotropism (affinity 
of tumour cells for certain tissues) is also suggested. 
As the adrenal parenchyma lacks lymphatic vessels, 
lymphomagenesis outside the organs before ‘homing’ to 
the adrenals is proposed. Chemokine- and microRNA-
driven organotropism in CNS and testicular lymphoma is 
under investigation, and similar mechanisms could exist 
in the pathophysiology of primary adrenal lymphoma 
(3). The authors pinpoint that more research is needed to 
explain the pathophysiology and bilaterality of primary 
adrenal lymphoma. B-symptoms are associated with 
bilaterality, thought to reflect greater systemic cytokine-
effects from lymphomas with larger tumour burden and 
greater access to blood and lymphoid vessels. There was 
a significant association between bilaterality and adrenal 
insufficiency. No concrete example of unilaterality and 
adrenal insufficiency was mentioned. On the other 
hand, even small primary adrenal lymphomas have been 
associated with adrenal insufficiency. This observation has 
led to a suggestion that the correlation between tumor size 
and adrenal insufficiency may be weak or absent (3). The 
percentage of patients with adrenal failure is considerably 
higher than in bilateral adrenal metastases from 
carcinoma (3–8%) (4). Cytokine-driven paracrine effects 
of lymphoma cells on adrenal gland microenvironment is 
suggested. The exact mechanisms are uncertain. Adrenal 
insufficiency in metastatic carcinoma is thought to reflect 
tumor replacement of functional tissue and interruption 
of vascular supply rather than cytochemical effects.
We present two cases of primary adrenal lymphoma 
manifesting as adrenal insufficiency with bilateral adrenal 
masses. One of the patients experienced almost total 
regression of the masses on treatment with standard 
replacement therapy alone, before subsequent aggressive 
regrowth. The other was biopsied during primary evaluation 
and responded to a combination of cytostatic therapy and 
radiation. Both patients presented with adrenal failure at 
an older age than expected for autoimmune adrenalitis. 
Negative 21-hydroxylase antibodies raised suspicion 
of an uncommon cause, and both had adrenal lesions 
pointing toward malignant disease. Adrenal lesions may 
have several causes, and biopsy should be taken when 
pheochromocytoma is biochemically excluded. The 
possible tumor-reducing effect of replacement therapy in 
one of our cases confused and delayed the diagnostics. 
Glucocorticoids are part of the standard regimen for several 
lymphoid cancers, due to steroid sensitivity of tumor 
cells that seems to be more pronounced for immature 
lymphoid cells (4). Glucocorticoids have direct actions 
on gene transcription through glucocorticoid response 
elements (GREs) and indirect actions through interaction 
with transcription factors. Effects on immune cells include 
inhibition of nuclear factor kappa B (NF-κB) and AP-1 (5, 
6). NF-κB is a transcription factor for cytokines and genes 
involved in lymphocyte development, inflammatory 
response and apoptosis. AP-1 is also a proinflammatory 
transcription factor (6). In our case number two, 
tumor regress was seen shortly after starting cortisone 
replacement therapy. Because of the strong correlation in 
time between treatment initiation and tumor shrinking, 
steroid sensitivity rather than spontaneous recovery seems 
to explain the regression. Obviously, this postulation will 
never be confirmed. Supporting our theory, there are 
no previous reports describing spontaneous regression 
of primary adrenal lymphoma. Initial recovery might 
be explained by primary indolent tumor histology 
transforming into a more aggressive type. In lack of 
biopsy, this hypothesis will remain unconfirmed. Diffuse 
large B-cell lymphoma has a reported 3-, 6- and 12-month 
survival of 67, 46 and 20%, respectively (3). As described 
in the section on 'Case presentations', one of our patients 
died of CNS-lymphoma 9 years after first presentation. 
The other one had no clinical signs of recurrence at the 
last follow-up at the haematology outpatient clinic. It is 
now nearly 3 years after first presentation and about 2 
years after diagnosis of diffuse large-cell B-cell lymphoma 
and initiation of chemotherapy.
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Primary adrenal failure with negative 21-hydroxylase 
antibodies should be evaluated radiologically. As outlined 
in the European guidelines on adrenal nodules (7), 
patients with adrenal lesions should be discussed in a 
multidisciplinary team if imaging is not consistent with 
benign etiology. In general, biopsy is not recommended as 
part of diagnostic work-up unless there is a history of extra-
adrenal malignancy. Lymphoma and infiltrative/infectious 
processes are mentioned as potential differential diagnoses 
where biopsy has a role in evaluation. Adrenalectomy 
is considered a better option than biopsy in most cases. 
Bilateral adrenal masses should be evaluated in the same 
way as unilateral lesions with separate characterization 
of each lesion. Given the high proportion of bilaterality 
and adrenal insufficiency in primary adrenal lymphoma, 
we find it reasonable to perform biopsy in patients with 
both characteristics when pheochromocytoma is excluded 
biochemically. Biopsy should be performed quickly to 
avoid potential steroid influences.
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